AU2021238928A1 - Treatment of upper facial lines - Google Patents

Treatment of upper facial lines Download PDF

Info

Publication number
AU2021238928A1
AU2021238928A1 AU2021238928A AU2021238928A AU2021238928A1 AU 2021238928 A1 AU2021238928 A1 AU 2021238928A1 AU 2021238928 A AU2021238928 A AU 2021238928A AU 2021238928 A AU2021238928 A AU 2021238928A AU 2021238928 A1 AU2021238928 A1 AU 2021238928A1
Authority
AU
Australia
Prior art keywords
asn
modified bont
bont
units
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021238928A
Other languages
English (en)
Inventor
Nicolae GRIGORE
Philippe Picaut
Katie RUFFLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of AU2021238928A1 publication Critical patent/AU2021238928A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Massaging Devices (AREA)
  • Percussion Or Vibration Massage (AREA)
AU2021238928A 2020-03-16 2021-03-16 Treatment of upper facial lines Pending AU2021238928A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003813.9 2020-03-16
GBGB2003813.9A GB202003813D0 (en) 2020-03-16 2020-03-16 Treatment of upper facial lines
PCT/GB2021/050659 WO2021186167A1 (en) 2020-03-16 2021-03-16 Treatment of upper facial lines

Publications (1)

Publication Number Publication Date
AU2021238928A1 true AU2021238928A1 (en) 2022-09-01

Family

ID=70453766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021238928A Pending AU2021238928A1 (en) 2020-03-16 2021-03-16 Treatment of upper facial lines

Country Status (11)

Country Link
US (2) US20230346674A1 (enExample)
EP (1) EP4120997A1 (enExample)
JP (2) JP2023517727A (enExample)
KR (1) KR20220154739A (enExample)
CN (1) CN115279337A (enExample)
AU (1) AU2021238928A1 (enExample)
BR (1) BR112022018457A2 (enExample)
CA (1) CA3166944A1 (enExample)
GB (1) GB202003813D0 (enExample)
TW (1) TW202140522A (enExample)
WO (1) WO2021186167A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US12011284B2 (en) * 2020-05-19 2024-06-18 Peachy Corp. Systems and methods for preventing and treating wrinkles
GB202206362D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of upper facial lines
GB202206361D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of a facial dystonia
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2025093845A1 (en) * 2023-11-01 2025-05-08 Ipsen Biopharm Limited Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
AU2023471835A1 (en) * 2023-11-01 2026-04-30 Ipsen Biopharm Limited Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
EP2524963B1 (en) 2011-05-19 2018-10-31 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
MX359480B (es) 2012-05-30 2018-09-28 President And Fellows Of Harvard College Star Neurotoxina botulínica diseñada.
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
EP4120997A1 (en) 2023-01-25
GB202003813D0 (en) 2020-04-29
KR20220154739A (ko) 2022-11-22
TW202140522A (zh) 2021-11-01
WO2021186167A1 (en) 2021-09-23
US20230346674A1 (en) 2023-11-02
US20260207462A1 (en) 2026-07-23
JP2026097980A (ja) 2026-06-16
CN115279337A (zh) 2022-11-01
JP2023517727A (ja) 2023-04-26
CA3166944A1 (en) 2021-09-23
BR112022018457A2 (pt) 2022-11-01

Similar Documents

Publication Publication Date Title
US20230346674A1 (en) Treatment of Upper Facial Lines
US20230248811A1 (en) Treatment of Limb Spasticity
US20250179461A1 (en) Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject
EP4401759B1 (en) Modified bont/a for use in the treatment of cervical dystonia
US20250177278A1 (en) Treatment of upper facial lines
US20250213662A1 (en) Bont/a for use in treating a facial dystonia
RU2846028C1 (ru) Лечение морщин верхней части лица
RU2841585C1 (ru) Модифицированный ботулинический нейротоксин для лечения спастичности конечностей
HK40078498A (en) Treatment of upper facial lines
WO2025093845A1 (en) Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines
HK40110371A (en) Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
CN117979988A (zh) 用于治疗影响受试者眼睑肌肉的疾病的修饰的BoNT/A
HK40078497A (en) Modified botulinum neurotoxin for treating limb spasticity